JENBURPH1,037.80

Jenburkt Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAKPLMAKERSLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation2.32.73.1
Changes in Working Capital
+ Inventories-0.2-0.3-4.8
+ Trade Receivables — Current-3.7-1.1-1.0
+ Trade Payables — Current0.21.9-0.1
Cash from Operating Activities
Profit Before Tax (per I/S)35.243.950.5
Cash from Operating Activities8.127.926.5
Cash from Investing Activities
+ Disp of Fixed Assets0.00.0
+ Purchase of Investments (Equity / Debt)26.837.639.1
+ Dividends Received — Investing0.10.10.2
Cash from Investing Activities-0.6-17.0-19.5
Cash from Financing Activities
+ Payment of Lease Liabilities0.50.60.6
Cash from Financing Activities-7.1-7.6-8.9
Net Changes in Cash0.53.2-1.8
Reference Items
EBITDA30.537.240.2
EBITDA Margin %21.4924.5323.81
Free Cash Flow (CFO − Capex)8.127.926.5
Cash Flow to Net Income0.310.870.76
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.